Standard Biotools Valuation
| LAB Stock | USD 1.60 0.02 1.23% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Standard Biotools has a current Real Value of $0.98 per share. The regular price of the company is $1.6. Our model measures the value of Standard Biotools from inspecting the company fundamentals such as Shares Outstanding of 372.26 M, operating margin of (0.29) %, and Return On Equity of -0.37 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Standard Biotools' valuation include:
Price Book 1.2172 | Enterprise Value 318.8 M | Enterprise Value Ebitda (19.22) | Price Sales 3.8204 | Enterprise Value Revenue 2.0446 |
Overvalued
Today
Please note that Standard Biotools' price fluctuation is extremely dangerous at this time. Calculation of the real value of Standard Biotools is based on 3 months time horizon. Increasing Standard Biotools' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Standard Biotools is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Standard Stock. However, Standard Biotools' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.6 | Real 0.98 | Target 0.55 | Hype 1.59 | Naive 1.27 |
The real value of Standard Stock, also known as its intrinsic value, is the underlying worth of Standard Biotools Company, which is reflected in its stock price. It is based on Standard Biotools' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Standard Biotools' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Standard Biotools helps investors to forecast how Standard stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Standard Biotools more accurately as focusing exclusively on Standard Biotools' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Standard Biotools' intrinsic value based on its ongoing forecasts of Standard Biotools' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Standard Biotools' closest peers. If more than one evaluation category is relevant for Standard Biotools we suggest using both methods to arrive at a better estimate.
Standard Biotools Cash |
|
Standard Valuation Trend
Comparing Standard Biotools' enterprise value against its market capitalization is a good way to estimate the value of Standard Biotools uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Standard Biotools Total Value Analysis
Standard Biotools is now forecasted to have company total value of 318.76 M with market capitalization of 595.61 M, debt of 98.21 M, and cash on hands of 81.31 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Standard Biotools fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
318.76 M | 595.61 M | 98.21 M | 81.31 M |
Standard Biotools Investor Information
About 73.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.22. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Standard Biotools has Price/Earnings To Growth (PEG) ratio of 0.31. The entity recorded a loss per share of 0.69. The firm had not issued any dividends in recent years. Standard Biotools had a split on the 6th of December 2001. Based on the key indicators related to Standard Biotools' liquidity, profitability, solvency, and operating efficiency, Standard Biotools is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Standard Biotools Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Standard Biotools has an asset utilization ratio of 32.92 percent. This suggests that the Company is making $0.33 for each dollar of assets. An increasing asset utilization means that Standard Biotools is more efficient with each dollar of assets it utilizes for everyday operations.Standard Biotools Ownership Allocation
Standard Biotools shows a total of 372.26 Million outstanding shares. The majority of Standard Biotools outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Standard Biotools to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Standard Biotools. Please pay attention to any change in the institutional holdings of Standard Biotools as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Standard Biotools Profitability Analysis
The company reported the last year's revenue of 106.34 M. Reported Net Loss for the year was (74.66 M) with loss before taxes, overhead, and interest of (1.45 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Standard Biotools' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Standard Biotools and how it compares across the competition.
About Standard Biotools Valuation
The stock valuation mechanism determines Standard Biotools' current worth on a weekly basis. Our valuation model uses a comparative analysis of Standard Biotools. We calculate exposure to Standard Biotools's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Standard Biotools's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 50.5 M | 48.5 M | |
| Pretax Profit Margin | (0.70) | (0.73) | |
| Operating Profit Margin | (0.72) | (0.76) | |
| Net Loss | (0.70) | (0.74) | |
| Gross Profit Margin | 0.47 | 0.63 |
Standard Biotools Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 79.2 M |
Standard Biotools Current Valuation Indicators
Valuation refers to the process of determining the present value of Standard Biotools and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Standard we look at many different elements of the entity such as Standard's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Standard Biotools, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Standard Biotools' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Standard Biotools' worth.Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |